Harnessing ruthenium(II) as photodynamic agents: Encouraging advances in cancer therapy

Liu, Jiangping; Zhang, Chen; Rees, Thomas W.; Ke, Libing; Ji, Liang‐Nian; Chao, Hui

doi:10.1016/j.ccr.2018.03.002

Cited by 170 publications

(114 citation statements)

References 154 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…[8] Ruthenium(II) polypyridyl complexes, including TLD1433 (4; Figure 1), the first metal-based photosensitizer without a tetrapyrrolic moiety to enter clinical trials for nonmuscle invasive bladder cancer PDT (ClinicalTrials.gov, identifier NCT03053635), [6] are attracting significant attention as PDT photosensitizers, as are luminescent polypyridyl complexes of Ir III , Os II and Re I . [9] In the next sections, we present examples of promising new photosensitizers and consider in more detail their mechanism of action, with particular focus on their interaction with proteins upon irradiation. We also highlight efforts to improve delivery of metal-based photosensitizers to Peter Sadler's group at the University of Warwick.…”

Section: Pdt Agentsmentioning

confidence: 99%

New Designs for Phototherapeutic Transition Metal Complexes

et al. 2019

View full text Add to dashboard Cite

In this Minireview, we highlight recent advances in the design of transition metal complexes for photodynamic therapy (PDT) and photoactivated chemotherapy (PACT), and discuss the challenges and opportunities for the translation of such agents into clinical use. New designs for light‐activated transition metal complexes offer photoactivatable prodrugs with novel targeted mechanisms of action. Light irradiation can provide spatial and temporal control of drug activation, increasing selectivity and reducing side‐effects. The photophysical and photochemical properties of transition metal complexes can be controlled by the appropriate choice of the metal, its oxidation state, the number and types of ligands, and the coordination geometry.

show abstract

Section: Pdt Agentsmentioning

confidence: 99%

New Designs for Phototherapeutic Transition Metal Complexes

et al. 2019

View full text Add to dashboard Cite

show abstract

“…[4] Ru II complexes, especially Ru II polypyridyl complexes, arep romisingp hotosensitizers (PSs) in PDT applicationso wing to their high thermal, chemical, and photochemical stabilities,a nd high quantum yields. [10] Amongt hem,m etal-organic framework (MOF) nanocarrier-based nanoplatformsh ave been developed rapidly, becauseo ft heir high surfacea rea, substantial pore structure, and alterablel igands, whichc an produce therapeutic treatmentt hrough loadinga gents by multiple methods. However,p oor waters olubility,w eak resistance to aggregation, and low selectivity towards tumorso fR u II polypyridyl complexes limit their PDT applications as PSs.…”

Section: Introductionmentioning

confidence: 99%

A Ru^II Polypyridyl Alkyne Complex Based Metal–Organic Frameworks for Combined Photodynamic/Photothermal/Chemotherapy

Dong

et al. 2020

Chemistry A European J

View full text Add to dashboard Cite

Despite drug delivery nanoplatformsr eceivinge xtensive attention,d evelopment of as imple, effective, and multifunctional theranostics nanoplatform stillr emains a challenge. Herein, av ersatile nanoplatformb ased on az irconium framework (UiO-66-N 3 )w as synthesized, which demonstrated ac ombined photodynamic therapy (PDT), photothermal therapy (PTT), and chemotherapy (CT) for cancert reatment. AR u II polypyridyl alkynec omplex (Ra) as ap hotosensitizer was modified into an anoplatformb yc lick reactions for the first time. When exposed to suitable light irradiation, the as-preparedmultifunctional nanoplatform (UiO-Ra-DOX-CuS) not only demonstrated efficient 1 O 2 generation, but also exhibited excellent photothermal conversion ability.I n particular, the nanotherapeutic agentp resented ad ual-stimuli response;e ither acidic environment or NIR laser irradiation would trigger the drug release. The synergetic efficacy of UiO-Ra-DOX-CuS combinedP DT,P TT,a nd CT,w hich was evaluated by cell experiments. Moreover,t he designc ould promotet he development of Ru II polypyridyl alkyne complexesb ased multifunctional nanoparticles and multimodal cancert reatment.[a] Dr.Supporting information and the ORCID identification number(s) for the author(s) of this articlecan be found under: https://doi.

show abstract

“…Next to the already approved PDT PSs, which are based on a tetrapyrrolic scaffold (i.e., porphyrins, chlorins, phthalocyanines), the development of Ru II polypyridyl complexes as PDT PSs is receiving more attention due to their ideal photophysical and photochemical properties, which include, among others, high water solubility, high chemical stability and photostability, intense luminescence, large Stokes shifts, high 1 O 2 production –. These attractive features have allowed one of such complexes, namely TLD‐1433, to enter into clinical trial as a PDT PS against bladder cancer .…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Characterization of an Epidermal Growth Factor Receptor‐Selective Ru^II Polypyridyl–Nanobody Conjugate as a Photosensitizer for Photodynamic Therapy

et al. 2019

View full text Add to dashboard Cite

There is a current surge of interest in the development of novel photosensitizers (PSs) for photodynamic therapy (PDT), as those currently approved are not completely ideal. Among the tested compounds, we have previously investigated the use of RuII polypyridyl complexes with a [Ru(bipy)2(dppz)]2+ and [Ru(phen)2(dppz)]2+ scaffold (bipy=2,2′‐bipyridine; dppz=dipyrido[3,2‐a:2′,3′‐c]phenazine; phen=1,10‐phenanthroline). These complexes selectively target DNA. However, because DNA is ubiquitous, it would be of great interest to increase the selectivity of our PDT PSs by linking them to a targeting vector in view of targeted PDT. Herein, we present the synthesis, characterization, and in‐depth photophysical evaluation of a nanobody‐containing RuII polypyridyl conjugate selective for the epidermal growth factor receptor (EGFR) in view of targeted PDT. Using ICP‐MS and confocal microscopy, we could demonstrate that our conjugate has high selectivity for the EGFR receptor, which is a crucial oncological target because it is overexpressed and/or deregulated in a variety of solid tumors. However, in contrast to expectations, this conjugate was found to not produce reactive oxygen species (ROS) in cancer cells and is therefore not phototoxic.

show abstract

Harnessing ruthenium(II) as photodynamic agents: Encouraging advances in cancer therapy

Cited by 170 publications

References 154 publications

New Designs for Phototherapeutic Transition Metal Complexes

New Designs for Phototherapeutic Transition Metal Complexes

A Ru^II Polypyridyl Alkyne Complex Based Metal–Organic Frameworks for Combined Photodynamic/Photothermal/Chemotherapy

Synthesis and Characterization of an Epidermal Growth Factor Receptor‐Selective Ru^II Polypyridyl–Nanobody Conjugate as a Photosensitizer for Photodynamic Therapy

Contact Info

Product

Resources

About

Harnessing ruthenium(II) as photodynamic agents: Encouraging advances in cancer therapy

Cited by 170 publications

References 154 publications

New Designs for Phototherapeutic Transition Metal Complexes

New Designs for Phototherapeutic Transition Metal Complexes

A RuII Polypyridyl Alkyne Complex Based Metal–Organic Frameworks for Combined Photodynamic/Photothermal/Chemotherapy

Synthesis and Characterization of an Epidermal Growth Factor Receptor‐Selective RuII Polypyridyl–Nanobody Conjugate as a Photosensitizer for Photodynamic Therapy

Contact Info

Product

Resources

About

A Ru^II Polypyridyl Alkyne Complex Based Metal–Organic Frameworks for Combined Photodynamic/Photothermal/Chemotherapy

Synthesis and Characterization of an Epidermal Growth Factor Receptor‐Selective Ru^II Polypyridyl–Nanobody Conjugate as a Photosensitizer for Photodynamic Therapy